ALTRAZEAL LIFE SCIENCES INC — Department of Defense SBIR Phase II: RESEARCH AND DEVELOPMENT FOR ARMY PHASE II SBIR MONTH 1-24 PROJECT TITLED, DEVELOPING AN I
ALTRAZEAL LIFE SCIENCES INC — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $1,155,968 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Altrazeal Life Sciences Inc received over $1.1 million from the Department of Defense to develop a product that prevents sepsis in wounded soldiers during initial battlefield treatment. The project focuses on creating an ideal first-use agent for trauma wounds in combat situations.
- Amount
- $1,155,968
- Agency
- Department of Defense · Defense Health Agency
- Program / Phase
- SBIR · Phase II
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- TX
- Period
- 2022-09-06 → 2027-01-05
Technology domains
Description
RESEARCH AND DEVELOPMENT FOR ARMY PHASE II SBIR MONTH 1-24 PROJECT TITLED, DEVELOPING AN IDEAL FIRST USE AGENT TO PREVENT SEPSIS IN TRAUMA WOUNDS DURING CARE UNDER FIRE